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Adjuvant Therapies in Colon 
Cancer
Thiru Prasanna and Desmond Yip
Abstract
Most of the patients with localized colon cancer undergo curative resection. 
However, significant number of patients will recur with metastatic disease, 
especially those with node positive cancer. Adjuvant chemotherapy has shown to 
improve cure rate and survival by eradicating micrometastases. The benefit of adju-
vant therapy is well established in node-positive cancers, while their role in stage 
II cancer is not well defined. A number of molecular markers have been identified 
that are prognostic and/or predictive in colon cancer. Such molecular markers, and 
other clinicopathological features play an important role in selection of appropriate 
therapy and duration of treatment. Emerging evidence for the utility of genomic 
profiling or detection of circulating tumor DNA (ctDNA) are promising which may 
further facilitate decision making in the future. This chapter reviews the evolution 
of adjuvant therapy for resected colon cancer, the current evidence and the factors 
influence the choice of therapy.
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1. Introduction
Colon cancer is a major cause of morbidity in the world and the second most 
common cause of cancer death. Most patients undergo curative resection of the 
primary colon cancer and removal of regional lymph nodes. Colon cancer mortality 
rates have improved over the years with the advancement of surgical techniques, 
diagnostic modalities and systemic therapy (Figure 1). Most important prognostic 
determinant is the stage of the cancer. The original pathological staging system used 
for colon cancer was the Dukes staging system which was based on the extent of 
penetration of the cancer through the bowel wall and whether there was involve-
ment of regional lymph nodes (Table 1). It was originally described for rectal 
cancer but applied to colon cancer as well [1].
Staging of colon cancer has been further refined in detail and standardized accord-
ing to the AJCC (American Joint Committee for Cancer)/UICC (Union for International 
Cancer Control) TNM staging system of which the latest version is the eighth edition 
which was adopted in 2018 [3]. The tumor and node definitions are shown in Table 2. 
Primary tumor and nodal factors define the stages as shown in Table 3.
The risk of recurrence increases with the stage, especially when there are nodal 
metastases. Postoperative adjuvant chemotherapy is utilized to eradicate the 
micrometastases which reduce the risk of recurrence and improve the cure rate. The 
role of adjuvant chemotherapy is well defined I stage III colon cancer; however, it 
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T—Primary tumor
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
Tis Carcinoma in situ: intramucosal (involvement of lamina propria with no extension 
through muscularis mucosae)
T1 Tumor invades submucosa (through muscularis mucosae but not into the muscularis 
propria)
T2 Tumor invades muscularis propria
T3 Tumor invades through muscularis propria into pericolorectalic (subserosal) tissues
T4 Tumor invades the visceral peritoneum or invades or adheres to adjacent organ or 
structure
T4a Tumor penetrates to the surface of the visceral peritoneum (including gross perforation of 
the bowel through areas of inflammation to the surface of the visceral peritoneum)
T4b Tumor directly invades or adheres to other organs or structures
N - Regional lymph node
NX Regional lymph nodes cannot be assessed
NO No regional lymph nodes metastases
Figure 1. 
Colon cancer related mortality from 1975 to 2010, (A) in males and (B) in females. Figures are from 
International Agency for Research on Cancer, global cancer observatory website [2].
Stage Description
Dukes A Tumor confined to within submucosa
Dukes B1 Tumor penetrates muscularis propria but not through bowel wall
Dukes B2 Tumor penetrates through bowel wall
Dukes C1 Tumor not through bowel wall with lymph node metastases
Dukes C2 Tumor through bowel wall with lymph node metastases
Table 1. 
Dukes staging system for colorectal cancer.
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remains controversial in stage II. This chapter reviews the role of adjuvant therapies 
in resected colon cancer.
2. Primary treatment of colon cancer
About 70–80% of patients diagnosed with localized non-metastatic colorectal 
cancer undergo curative resection which is the main modality of treatment for those 
N1 One to three regional nodes are positive (tumor in lymph nodes measuring >0.2 mm), or 
any number of tumor deposits are present and all identifiable lymph nodes are negative
N1a One regional lymph node is positive
N1b Two or three regional lymph nodes are positive
N1c No regional lymph nodes are positive, but there are tumor deposits in the
• subserosa
• mesentery
• or non-peritonised pericolic or perirectal/mesorectal tissues
N2 Four or more regional lymph nodes are positive
N2a Four to six regional lymph nodes are positive
N2b Seven or more regional lymph nodes are positive
M - Distant metastasis
Mo No distant metastasis by imaging, etc.; no evidence of tumor in distant sites or organs
M1 Metastasis to one or more distant sites or organs or peritoneal metastasis is identified
Table 2. 
The tumor, node, metastasis (TNM) staging system.
Stage T N M
0 Tis N0 M0
I T1 N0 M0
T2 N0 M0
IIA T3 N0 M0
IIB T4a N0 M0
IIC T4b N0 M0
IIIA T1-T2 N1/N1c M0
T1 N2a M0
IIIB T3-T4a N1/N1c M0
T2-T3 N2a M0
T1-T2 N2b M0
IIIC T4a N2a M0
T3-T4a N2b M0
T4b N1-N2 M0
Table 3. 
Prognostic stage groups.
Colorectal Cancer
4
with good performance status and acceptable comorbidities. This is achieved by 
surgical resection of the primary tumor, anastomosis of the bowel and removal of 
12 or more regional lymph nodes. The aim of oncological resection is the complete 
removal of the tumor and potential lymphovascular spread with a clear margin of at 
least 5 cm proximally and distally for colon cancer, and minimal proximal margin of 
5 cm and distal of 2 cm for rectal carcinoma. Circumferential/radial margin clear-
ance of at least 1 mm is considered optimal. Endoscopic resection involves complete 
tumor resection and adjacent tissue in one block. This may be acceptable for those 
accept vigorous close surveillance and potential need for further surgical resection 
or those who are non-surgical candidates.
3. Adjuvant therapies
3.1 Drugs used: 5FU, capecitabine, oxaliplatin
3.1.1 5-Fluorouracil (5-FU)
5FU is an antimetabolite drug that inhibits DNA and RNA synthesis by acting 
as a false substrate in purine and pyrimidine synthesis thereby interfering in the S 
phase of the tumor cell cycle. It is metabolized by the rate limiting enzyme dihydro-
pyrimidine dehydrogenase. The main toxicities are related to mucosal inflammation 
and this presents clinically as mucositis, stomatitis and diarrhea. It can also cause 
nausea and myelosuppression. Rarely, it can cause cardiotoxicity presumably by 
inducing coronary artery spasm.
3.1.2 Capecitabine
Capecitabine is an oral fluropyrimidine prodrug which is taken up inside the 
tumor cells and metabolized to the active 5FU product by thymidine phosphorylase. 
Repeated oral administration mimicks the pharmacokinetics of protracted infu-
sional 5FU. The side effects are similar to 5FU in term of mucositis and diarrhea but 
hand-foot syndrome or palmar-plantar erythrodysesthesia with redness, tenderness 
and swelling of these areas is a common toxicity experienced.
3.1.3 Oxaliplatin
Oxaliplatin is a third-generation platinum drug which acts as an alkylating agent 
in causing DNA damage by intrastrand crosslinks. The drug is not nephrotoxic 
or ototoxic but the main side effect is cold related dysesthesia which can lead to 
cumulative sensory neuropathy. It is moderately emetogenic and myelosuppressive. 
It exhibits synergy with fluoropyrimidines and so is normally used in combination 
with this class of cytotoxics.
3.2 Historic data; levamisole, folinic acid
3.2.1 Levamisole
Levamisole is an anti-helminthic drug that is used in veterinary medicine. It was 
found to have effects on phagocytosis and chemotactic responses of neutrophils as 
well as on stimulation of lymphocyte proliferation, differentiation and cytotoxicity 
suggesting an immunomodulatory effect. Preclinical studies suggested an antimeta-
static effect in tumor xenograft models.
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The initial Leicester trial randomized patients after curative surgery either to 
observation, 5FU, or 5FU plus levamisole. 5FU was administered intravenously for 
# days following surgery, and then orally once weekly for 6 months; levamisole 
was administered for only three postoperative days. After 5 years of follow-up, the 
survival of patients randomized to 5FU plus levamisole was significantly prolonged 
compared with 5FU alone (p = 0.02) or observation (p = 0.045).
Levamisole alone, given intermittently for 1 year, did not produce a survival 
benefit in an EORTC trial with Dukes C colon cancer patients [4]. In the NCCTG 
trial levamisole was inferior to the combination with 5FU [5].
Two trials the US Intergroup 0035 and the Netherlands Adjuvant Colorectal 
Cancer Project (NACCP) study both found a significant benefit of 5FU and levami-
sole in the adjuvant therapy of resected colon cancer compared to observation [6]. 
A subsequent meta-analysis of these two studies found that after adjustment for the 
total planned 5FU dose the effect of levamisole became non-significant. Subsequent 
trials disproved the benefit of levamisole in adjuvant therapy of colon cancer [7, 8].
3.2.2 Leucovorin (folinic acid)
Leucovorin is an active metabolite of folic acid which works by enhancing 
enzymatic binding of 5FU onto thymidylate synthetase to prolong the half-life of 
5 U and therefore potentiates the 5FU. It is not a cytotoxic agent on its own. Rarely, 
it can cause rash or itch.
Clinical trials compared 5FU-leucovorin regimens to 5FU-levamisole regimens 
and disproved the benefit of levamisole. The INT-0089 and QUASAR studies have 
demonstrated that there is no difference in outcome between the use of high dose or 
low dose leucovorin [7, 8].
3.3 Stage I colon cancer
Stage 1 colon cancer is often an incidental finding in those patients undergoing 
polypectomy. Therefore, pedunculated polyps should be resected with excision of 
the stalk down to the base. When stage 1 colon cancer is found in a polyp that was 
completely excised with clear margin of more than 2 mm, further surgical excision 
may not be required, provided there are no high risk features such as lymphovascu-
lar invasion, poor cell differentiation, and malignant invasion beyond stalk. Such 
patients with high risk features should undergo further excision like segmental 
resection for complete staging. Sessile polyps with invasive cancers also can be 
managed with segmental colon resection unless they can be removed in one piece 
[9]. An estimated 5% of resected polyps and 20% of unresectable polyps contain 
invasive cancer [10]. Five-year survival rate for stage 1 colon cancer is more than 
95%, and adjuvant therapy is not indicated [11].
3.4 Stage II colon cancer
The role of adjuvant chemotherapy in stage II is not clearly defined. 5-year 
disease free survival for these patients is more than 80%. Because of this rela-
tively good prognosis, benefit from adjuvant 5FU-based chemotherapy is small 
and remains questionable given many of the trials are underpowered. In order to 
demonstrate a larger benefit or to unravel small differences with statistical sig-
nificance, a highly efficacious therapy or trials with larger samples are needed. To 
detect an absolute improvement in survival at 5 years by 4% with more than 90% 
power, 4700 patients with stage II colon cancer would be required. A retrospective 
study based on SEER-Medicare linked database explored the outcome of more 
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than 3000 patients without any adverse features depending whether they received 
chemotherapy within 3 months after surgery or not. Interestingly, 27% of patients 
received adjuvant therapy in this group without much evidence to support it [12]. 
They reported a 5-year survival of 75% for those who did not receive chemotherapy 
versus 78% in those who received therapy. High grade, younger age, low comorbidi-
ties and white race were more likely to receive chemotherapy. After adjusting for 
known variables there was no difference in survival (HR 0.91, 95% CI 0.77–1.09).
A number of trials have tried to address the role of adjuvant therapy in stage II 
colon cancer with conflicting results. QUASAR (Quick and Simple and Reliable), 
a large UK study investigated the role of adjuvant 5FU in this randomized con-
trolled trial [13]. This study enrolled more than 3000 patients with (91%) stage II 
cancers (node-negative) which also included 30% rectal cancer. After a median 
follow up of 5.5 years, there was about 20% reduction in the relative risk of death 
(any cause mortality HR 0.82; 95% CI 0.70–0.95; p < 0.008) in those treated with 
chemotherapy compared to placebo controlled arm which translated into small but 
significant absolute survival benefit of 3.6% (95% CI 1.0–6.0). Despite significant 
results, number of pitfalls in this trial has raised questions with regard to the benefit 
seen. The median number of lymph nodes removed in this study was 6 (in more 
than 60% of patients <12 lymph nodes were removed) which is well below current 
standards. In addition, there was a group of patients who received radiation therapy 
(14%) and another proportion received portal vein infusion therapy (6%), which 
are not standard practice.
There were a number of meta-analyses which support the use of adjuvant 
therapy in stage II colon cancer including NSABP, NCCTG and IMPACT. 
International Multicenter Pooled Analysis of Colon Cancer Trial (IMPACT) was 
a pooled analysis of randomized trials, showed a 2% improvement in 5-year 
overall survival. In another analysis of more than 150,000 patients with stage 
II colon cancer from National Cancer Database reported survival advantage of 
adjuvant therapy (HR 0.76; p < 0.001) [14]. Gill et al. analyzed pooled individual 
patient data of 3302 patients with stage II and stage III colon cancers. Although 
there was a statistically significant improvement in disease free survival (by 
4%), overall survival difference (absolute benefit of 5%) was not significant 
[15]. The Adjuvant Colon Cancer End Points (ACCENT) collaboration analyzed 
individual patient data with regard to long term outcome after adjuvant therapy. 
Among 6900 patients with stage II cancers, there was 5% improvement survival 
at 8 years [16].
Given the conflicting data, adjuvant therapy in stage II colon cancer remains 
controversial. Several clinicopathological features and molecular markers are 
associated with poor prognosis in stage II colon cancers. These include T4 primary, 
bowel obstruction of peroration, poorly differentiated phenotype (including signet 
ring cells and mucinous) high pre-operative carcinoembryonic antigen (CEA), 
inadequate lymph node sampling (<13 nodes), lymphovascular space invasion and 
perineural invasion [17, 18]. Although most expert groups consider these factors 
as high risk features in stage II colon cancer, some discrepancy exist among their 
definition for high risk stage colon cancer [19–21]. While most expert groups 
recommend to consider these adverse factors when considering adjuvant therapy, 
there is limited evidence to suggest that the presence of one or risk factors are more 
likely to benefit from adjuvant therapy. In the landmark MOSAIQ trial, 434 patients 
were considered high risk stage II colon cancer. Although there was trend towards 
better disease-free survival in the FOLFOX arm compared to 5FU arm, overall 
survival was essentially similar [22]. The decision regarding adjuvant therapy in this 
setting will need to be individualized and take into account the patient’s preferences 
regarding therapy.
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3.4.1 Role of oxaliplatin
Two large phase III trials explored the role of oxaliplatin in stage II colon cancer; 
MOSAIC and NSABP C-07 which have virtually shown the lack of benefit of oxalipl-
atin in stage II colon cancer [22, 23]. Forty percent and 27% of patients were stage II 
in MOSAIC and NSABP C07 trials, respectively. An updated 10-year follow up report 
of MOSAIC confirmed the lack of benefit from oxaliplatin in stage II colon cancer. 
In fact there was a trend towards adverse outcome in low-risk stage II in MOSAIC, 
while there is a non-significant trend of improvement in disease free survival (7%) 
and overall survival (2%) [22]. No disease-free survival or overall survival benefit 
was seen in NSABP C-07 trial in patients with stage II colon cancer [23]. Therefore 
oxaliplatin is unlikely to benefit most patients with stage II colon cancer; however, it 
may be appropriate to discuss oxaliplatin in those with extremely high risk features, 
given the findings from MOSAIC.
3.5 Stage III colon cancer
Patients with node positive colon cancer are at higher risk of recurrence with a 
5-year overall survival estimate of 40–60%. Adjuvant therapy is indicated for most 
patients with stage III disease to eliminate micro metastases and to improve disease 
free survival and overall survival. Combination 5FU/leucovorin and oxaliplatin 
regimen is the standard of care unless they are medically unfit to receive intensive 
chemotherapy where single agent 5FU/Leucovorin may be appropriate.
A landmark study in the 1990s established the benefit of adjuvant therapy in 
resected stage III colon cancer where 5FU/levamisole for 12 months decreased recur-
rence and improved survival [5]. Results remained significant at 5 years with a 41% 
reduction in recurrence and 33% reduction in death [24]. However subsequently 
leucovorin has emerged as an effective potentiator of anti-tumor activity of 5FU, 
whereas levamisole lacked significant biological activity. 5-FU is metabolized in can-
cer cells to 5-fluorouridine 5′-monophosphate (FUMP), by uridine monophosphate 
synthetase, with a resultant active form, 5-fluoro-2′-deoxyuridine 5′-monophos-
phate (FdUMP). FdUMP then forms a ternary complex with thymidylate synthase 
in the presence of reduced tetrahydro folate (5,10-CH2-THF) which eventually 
inhibit DNA replication. Leucovorin is metabolized into 5,10-CH2-THF and enhance 
formation of thymidylate synthase/5FU ternary complex and anti-tumor activ-
ity. Subsequent studies confirmed the lack of utility of levamisole and efficacy of 
leucovorin in combination with 5FU in adjuvant therapy of colon cancer [25].
Two large randomized studies established the role of oxaliplatin in the adju-
vant treatment of stage III colon cancer. Multicentre International Study of 
Oxaliplatin/5FU/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIQ ) 
utilized a 2 hour bolus infusional 5FU followed by 22 hours 5FU infusion along with 
oxaliplatin in a 2 weekly cycle (FOLFOX4) for 6 months in resected colon cancer 
patients (60% stage III and 40% stage II). A total of 2246 patients were randomized 
to receive either FOLFOX4 or 5FU/leucovorin. In the intention to treat popula-
tion FOLFOX4 significantly improved 5-year disease free survival (73.3% 67.4%) 
compared to 5FU/leucovorin (HR 0.80, 95% CI 0.68–0.93; p = 0.003). Overall 
survival at 6 years was 78.5% versus 76.0% (HR 0.84; 95% CI, 0.71–1.00; p = 0.04). 
In a subgroup analysis, there was 4.2% improvement by the addition of oxaliplatin 
in 6-year overall survival in stage III disease (72.9% versus 68.7%, HR =0.80; 95% 
CI =0.65–0.97; p = 0.023), however, no overall survival benefit was evident by the 
addition of oxaliplatin in stage II cancer (85% versus 83.3%, p = 0.65). In a 10-year 
updated analysis, results essentially remained consistent. Oxaliplatin was approved 
for adjuvant treatment of colon cancer and is the standard of care for most patients 
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with stage III colon cancer. The FOLFOX4 regimen is associated with more toxicity 
compared to 5FU/leucovorin, notably grade 3/4 neutropenia was 41% in FOLFOX4 
compared to 5% in 5FU/leucovorin and grade 3/4 diarrhea was 11% versus 7%. 
Oxaliplatin was associated with cold related dysesthesia and mostly reversible 
peripheral sensory neuropathy. Grade 3 neuropathy was reported in 12% of patients 
who received FOLFOX4. Although considered reversible, minority of patients may 
suffer long term or permanent sensory loss. About 30% of patients still had residual 
numbness at 12 months (5.9% grade 2/3) with another 24% experiencing some 
degree of neuropathy at 18 months from the end of treatment (3.9% grade 2/3).
A large second study confirmed the efficacy of oxaliplatin in adjuvant therapy 
for stage III colon cancer. NSABP C-07 enrolled 2409 patients with stage III (71%) 
and stage II (29%) colon cancer. They were randomized to receive either combina-
tion 5FU/leucovorin/oxaliplatin (FLOX) or 5FU/leucovorin. A weekly bolus 5FU 
Roswell Park regimen was used here instead of infusional 5FU. FLOX regimen 
improved disease-free survival compared to control arm (69.4% versus 64.2%; HR 
0.82; 95% CI 0.72–0.93; p = 0.002), however overall survival differences were not 
statistically different. (HR 0.88; 95% CI 0.72–1.02; P = 0.08) No interaction was 
seen between treatment on the stage, however treatment effect did vary by age 
overall survival significantly improved in patients younger than 70 (HR 0.80; 95% 
CI 0.68–0.95; p = 0.01) with no effect seen in older patients [23]. However, FLOX 
regimen was associated with high incidence of grade 3/4 diarrhea (38% versus 
32%) and hospitalization (5.5% versus 3%). Given the lack of survival benefit 
and toxicity with bolus 5FU regimen, infusional 5FU regimens like FOLFOX have 
become standard of care.
The XELOXA trial supported the benefit of oxaliplatin in combination with 
capecitabine. In this randomized trial, 1866 patients with stage III colon cancer 
were either treated with capecitabine/oxaliplatin or bolus 5FU/leucovorin regimen 
(Mayo clinic or Roswell Park) for 6 months. After a median follow up of 7 years 
disease free survival (63% versus 56%, HR 0.80; 95% CI; 0.69–0.93; p = 0.004) and 
overall survival (73% versus 67%, HR 0.83; 95% CI 0.70–0.93; p = 0.04) improved 
significantly compared to 5FU/leucovorin.
In all three trials oxaliplatin was associated with significant neurotoxicity 
which can be acute or chronic. Acute cold related neurotoxicity present as par-
esthesia or dysesthesia of hands and feet or muscular cramps including laryn-
gospasm. This is often reversible but tends to recur with each treatment. On the 
other hand chronic neuropathy causes primarily a sensory neuropathy in limbs is 
thought to be due to accumulation of platinum products in dorsal root ganglia in a 
dose -dependent manner. About 10–15% of patients experience severe neuropathy 
after cumulative dose of 780–850 mg/m2. Other clinical factors are implicated in 
the onset of neuropathy, but none shows strong association. Patents with existing 
other comorbidities such as diabetes, hypertension and smoking may be associ-
ated with higher incidence of neuropathy from oxaliplatin, these results were not 
statistically significant. But patients with diabetes seem to develop neuropathy at 
lower cumulative dose [26]. Another report suggests that incidence neuropathy 
may be less XELOX 3-wekely (130 mg/m2) regimen than FOLFOX 2-weekly 
(85 mg/m2) regimen [27]. Therefore, choice of oxaliplatin in the adjuvant treat-
ment of colon cancer should be based on individual assessment of risk of recur-
rence and other clinical factors.
3.5.1 Role of radiation
Adjuvant and neoadjuvant radiotherapy is routinely used in the treatment 
of rectal cancer and has an impact on reducing the local recurrence rate and 
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therefore improving local control. However, the use of this modality in non-rectal 
colon cancer is controversial and not supported by randomized controlled trials. 
It is however considered in the situation of T4 tumor which invades surrounding 
structures such as the bladder or the abdominal wall where there is a perceived 
high risk of local recurrence of the tumor. A retrospective analysis of 21,789 
patients with T4 colon cancer using the US SEER (Surveillance, Epidemiology 
and End Results) database found 1001 patient who received radiotherapy [28]. 
After adjustment for sex, age, N stage and tumor grade the relative risk of death 
from cancer at 5-years was 0.88 (95CI 0.8008–0.9779, p = 0.0165) in patients who 
received radiotherapy.
3.6 Role of adjuvant therapy for resected colorectal cancer metastases
Liver is the commonest site of metastases in colon cancer. Unlike many other 
solid organ cancers, metastasectomy improves survival in colorectal cancer, where 
5-year overall survival may reach 50%. The best postoperative management strat-
egy is not well defined, however, often perioperative chemotherapy is utilized in the 
form of FOLFOX or CAPOX with agents like irinotecan, anti-EGFR, or anti-VEFG 
therapy often added for eligible patients in the neoadjuvant setting if downstag-
ing was necessary. In the EORTC 40983 trial, perioperative chemotherapy was 
associated with 7.3% absolute increase in 3-year progression-free survival, however 
there was no difference in overall survival [29, 30]. Another Japanese study also 
did not show overall survival benefit with adjuvant chemotherapy [31]. Given the 
established role of adjuvant therapy in stage III colon cancer, despite lack of strong 
evidence many expert groups support perioperative or postoperative chemotherapy 
for resectable colorectal cancer metastases.
4. Molecular markers
4.1 Mismatch repair enzyme deficiency
Colon cancers that lack mismatch repair enzyme (dMMR) exhibit high mic-
rosatellite instability (MSI-High) and are associated with better prognosis com-
pared to those with proficient mismatch repair enzymes (pMMR). Consistently, 
frequency of dMMR is higher in stage II colon cancer (20%) compared stage III 
(12%) and stage IV (4%) [32]. In a seminal study by Ribic et al., reported the 
prognostic differences between dMMR and pMMR in 570 patients from 5 differ-
ent trials of 5FU based adjuvant chemotherapy (stage II and III) [33]. Five-year 
overall survival was significantly better in dMMR compared to pMMR(HR 0.31; 
95% CI, 0.14–0.72;p = 0.004). Furthermore, there was no survival difference 
between dMMR and pMMR among those who received adjuvant chemotherapy 
(HR 1.07; 95% CI, 0.62–1.86; p = 0.80). The benefit of adjuvant chemotherapy 
was restricted to those with pMMR only. Although not all studies are consistent, 
a systemic review of 32 trials supported the above finding [34]. The key enzyme 
involved 5FU metabolism in cancer cells, thymidylate synthase, is found to be 
overexpressed in dMMR colon cancers which confer resistance to 5FU based 
therapy. Therefore, most patients with stage II colon cancer would not benefit 
from 5FU (only) based adjuvant therapy. Nevertheless, the role of dMMR in 
adjuvant therapy for stage III colon cancer is less clear. Despite lack of prospective 
data, retrospective studies support the use of oxaliplatin based adjuvant therapy, 
although Sinicrope et al. reported reduced distant recurrence in stage III cancers 
after treatment with 5FU [35, 36].
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4.2 Other molecular markers
Lack of CDX2 was associated with lower 5-year survival rate compared to CDX2-
positive tumors, especially in stage II tumors (49% versus 87%, p = 0.003). CDX2 
was also predictive of treatment benefit with higher disease-free survival in CDX2-
negative tumors in both stage II and III tumors. This need to be further validated in 
prospective studies. The presence of BRAF V600E mutation confers a poor prognosis 
in colon cancer; however, concomitant loss of one or more MMR enzymes (dMMR) 
seems to improve the survival. In an analysis of three adjuvant chemotherapy trials 
of stage II and III colon cancer, BRAF mutation was not prognostic, however overall 
survival was poor among those with pMMR [32]. While another study of 2299 
patients from two NSABP trials showed similar results, where BRAF mutation was 
not predictive of oxaliplatin benefit [37]. The presence of RAS (KRAS and NRAS) 
mutation is associated with resistance to EGFR targeted therapy in metastatic colon 
cancer. Although the presence of KRAS mutation seems to confer poor prognosis, 
not all studies are consistent [32, 37–39]. Number of other molecular markers such 
as DCC, TP53, thymidylate synthase and POL-E are also found to have prognostic 
significance [40–43]. Despite emerging evidence of these molecular markers, their 
predictive value is still not validated in clinical practice and they are not routinely 
considered in decision making regarding adjuvant therapy, except for MMR status.
Gene expression profiling has been utilized to characterize colon cancers and to 
identify gene signatures that could be predictive and prognostic. A number of com-
mercial assays are developed in the recent past (OncoDefender-CRC, ColonPRS, 
ColoPrint colon cancer recurrence assay, GeneFx colon) but none have been 
approved for routine use in clinical practice. The Oncotype-DX colon cancer assay 
is perhaps the most validated tool which is a 12-gene assay developed to predict the 
recurrence score in stage II colon cancer. It was validated using prospective data 
from large studies including QUASAR, CALGB9581 and SUNRISE [44–46]. Despite 
the ability in predicting the risk of recurrence with confidence, it is unclear whether 
patients in higher risk category will benefit from adjuvant chemotherapy. A treat-
ment score was developed using the data from QUASAR, but it was not predictive 
of the treatment effect. At this stage the data are insufficient to recommend routine 
use of multi-gene assays when deciding adjuvant therapy for stage II colon cancer.
4.3 Circulating tumor DNA (ctDNA)
Gene sequencing of colorectal cancer have identified number of common 
somatic mutations and these tumor-specific mutations can be utilized to detect the 
tumor DNA (ctDNA) in the cell free component of peripheral blood. Detectable 
ctDNA after surgical resection or after completion of adjuvant chemotherapy seem 
to be associated with high risk of recurrence. In a study of 230 patients with resected 
stage II colon cancer, 14 patients out of 178 who did not receive adjuvant chemo-
therapy had detectable ctDNA. Eleven of the 14 (79%) developed recurrence at a 
median follow up of 27 months. Among those who received chemotherapy 3/44 had 
detectable ctDNA and all of them have relapsed within 11 months [47]. In metastatic 
setting, changes in ctDNA correlate with radiological responses [48]. Consistently 
in the early stage colon cancer, patients who clear ctDNA after adjuvant therapy 
have favorable prognosis [49]. Currently available data suggest that ctDNA is robust 
marker of minimal residual disease after surgery or after adjuvant chemotherapy 
with good prognostic and predictive value. Although current assays used to detect 
ctDNA have high specificity and positive predictive value, the sensitivity of these 
assays need optimization. In addition, a consensus on the methodology and larger 
number of prospective trials are needed before their routine use in clinical practice.
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5. Timing of chemotherapy
Adjuvant therapy should be initiated as soon as patient has recovered from 
surgery with complete healing of surgical wounds which usually takes about 
2–4 weeks. A meta-analysis in 2019 which included 34 comparative studies of 
resected colon cancer reported that delay in treatment beyond 6–8 weeks was 
associated with inferior survival (HR 1.27,95% CI 1.21–1.33; p < 0.001) [50]. 
Another review which included more than 15,000 patients concluded that a 
4-week increase in time to initiate adjuvant chemotherapy was associated with a 
14% relative decrease in disease free survival and overall survival [51]. A number 
of other studies have consistent findings suggesting inferior outcomes when 
chemotherapy was initiated more than 6–8 weeks. However, most of these studies 
are retrospective in nature and potentially biased by confounding factors such as 
comorbidities, post-operative complications, and emergency resections which are 
all likely to delay the recovery.
6. Duration of therapy
The recommendations for duration of adjuvant therapy for colon cancer are 
evolving. Early adjuvant trials treated patients for 12 months with 5FU/levamisole 
which was the standard of care in 1990s. Subsequent studies revealed 6 months of 
therapy was at least comparable to 12 months which became the standard of care 
in late 1990s [25, 52]. MOSAIQ an NSABP C-07 trials utilized 6 months of oxali-
platin and 5FU based regimen which remained as standard practice until recently 
the IDEA (International Duration Evaluation of Adjuvant Chemotherapy) col-
laboration study explored non-inferiority of 3 months of adjuvant therapy versus 
6 months. IDEA collaboration study was a prespecified exploratory combined anal-
ysis of six separate international randomized trials of 6 versus 3 months of oxalipla-
tin based adjuvant therapy. Although non-inferiority of 3-months was not proven 
in the intention to treat population, sub-group analysis revealed patients those who 
received capecitabine and oxaliplatin (CAPOX) for 3 months, 5-year disease free 
survival was non-inferior to 6 months, however 3 months of 5FU and oxaliplatin 
FOLFOX did not meet the non-inferiority margin [53, 54]. Among low risk patients 
(T1–3,N1) the 5-year overall survival benefit between 3 versus 6 months therapy 
was 89.6% versus 88.9% (absolute difference of 0.7%) whereas the absolute differ-
ence was 2.7 among higher risk patients (T4N2 and above). Therefore, in lower risk 
patients, 3 months of therapy is acceptable if CAPOX regimen was chosen, while 6 
months of therapy should be offered with FOLFOX regimen for others with stage 
III disease with clear discussion with patients regarding the small added benefit 
and risk of long-term neuropathy. 5FU/Leucovorin without oxaliplatin is offered 
as adjuvant therapy in stage III colon cancer sometimes, when patients are medi-
cally unfit or elderly. Six months adjuvant therapy is the standard recommendation 
in this situation, given absence of prospective data comparing 3 months versus 
6 months. Similarly, 6 months of 5FU based adjuvant therapy is standard in stage II 
colon cancer. However, patients with high risk stage II disease are sometimes treated 
with oxaliplatin based regimen. TOSCA trial investigated 3 months versus 6 months 
of adjuvant therapy in stage II and III colon cancer where one-third of them were 
stage II [55]. In the overall population, 6 months was superior to 3 months, how-
ever, 3 months of CAPOX regimen was non-inferior to 6 months. There were 1254 
patients with high risk stage II disease in the IDEA collaborative study (including 
TOSCA study) which investigated the optimal duration of adjuvant therapy [56]. 
Investigators concluded that 3 months of CAPOX may be non-inferior to 6 months 
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in high risk stage II cancers, reflecting the finding in stage III disease. Consistently 
3 months of FOLFOX was not non-inferior to 6 months.
7. Adjuvant therapy in elderly
Systemic chemotherapy in older adults may possess unique challenges due to 
comorbidities, and age-related organ dysfunction which may limit their life expec-
tancy. In addition the impact on quality of life from chemotherapy may be more 
prominent in older adults. Benefit of adjuvant chemotherapy in older adults is well 
established. A pooled analysis of seven randomized trials of adjuvant chemotherapy 
(5FU/levamisole or 5FU/leucovorin) in stage II and III found comparable overall 
survival and disease free survival benefit in patients of over 70 compared to those 
less than 70 [57]. Similar outcomes were seen in another analysis of prospective 
data from 85,934 patients [58]. Although it is not clearly determined whether older 
patients experience more toxicities from chemotherapy, an analysis of 37,568 patients 
from ACCENT database (Clinical Trials From the Adjuvant Colon Cancer Endpoints 
Database) reported early mortality was significantly higher among those who are 
>70 compared to younger patients [59]. A pooled analysis suggested no difference in 
toxicity from 5FU based therapy in older adults; however, it is important to consider 
that toxicity from 5FU may vary depending on the schedule, specially gastrointestinal 
side effects in older adults may be more frequent with bolus regimens compared to 
short term infusional regimens [60]. In addition capecitabine may be associated with 
more severe toxicities in older adults, especially in those with diminished renal func-
tion. In a phase 3 trial of stage III colon cancer, particular toxicities like diarrhea were 
higher among patients over 65 with capecitabine [61]. Similarly, in X-ACT trial which 
examined capecitabine versus bolus 5FU (Mayo clinic), treatment-related toxicity 
was higher in patients above 70 (51%) compared to those less than 70 (39%) [62].
Although oxaliplatin based adjuvant chemotherapy improves survival in stage 
III colon cancer, its role in older adults above 70 is debatable. Subset analysis of 
three large randomized trials failed to demonstrate survival advantage in older 
patients. In an updated analysis of the MOSAIQ study, addition of oxaliplatin did 
not improve survival in 315 patients above 70 years (HR 1.16; 95% CI, 0.83–1.7) [22]. 
NSABP C-07 study enrolled 396 patients over 70 years, and no added benefit was 
seen with oxaliplatin in either in disease free survival (HR 1.03; 95% CI 0.77–1.36) 
or overall survival (HR 1.18; 95% CI 0.68–1.62) [23]. Consistently XELOXA study 
failed to demonstrate benefit of oxaliplatin over capecitabine alone in patients above 
70 years (Disease free survival: HR 0.86; 95% CI, 0.64–1.16 and overall survival: HR 
0.98; 95% CI, 0.62–1.56) [63]. A pooled analysis of seven randomized trials from 
ACCENT database with more than 14,500 patients (including 2575 patients over 
70 years) suggested no survival advantage of oxaliplatin in those above 70 years 
(Disease free survival: HR 0.94; 95% CI, 0.78–1.13; Overall Survival: HR, 1.04; 95% 
CI, 0.85–1.27) [64]. However, it is unclear as to why addition of oxaliplatin was ben-
eficial in metastatic setting and not in early cancer setting. Therefore, with currently 
available data, oxaliplatin is not recommended for routine use in patients above 70 
who need adjuvant therapy, however, in those with high risk cancer and medical fit 
with good life expectancy, the benefit and risk of oxaliplatin should be discussed.
8. Drugs that are not routinely indicated as adjuvant therapy
Irinotecan, via its active metabolite SN-38 inhibits topoisomerase 1 enzyme, 
causing inhibition of DNA replication and cell death. Irinotecan has well 
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established activity in metastatic colorectal cancer in combination with 5FU/leu-
covorin and as single agent. However, three phase III randomized controlled trials 
have failed to show any benefit of irinotecan based regimens [65–67]. Bevacizumab 
and cetuximab have shown survival advantage in metastatic colon cancer when 
added to irinotecan or oxaliplatin based regimens. Bevacizumab is a vascular endo-
thelial growth factor inhibitor, failed to show benefit when added to FOLFOX or 
capecitabine [68–70]. The NCCTG-N0147 trial examined the utility of cetuximab 
which is a mouse/human chimeric monoclonal antibody that targets the epidermal 
growth factor receptor, with FOLFOX compared to FOLFOX alone in resected colon 
cancer [71]. The trial was closed prematurely after the interim analysis showed 
no benefit of cetuximab. This was confirmed in another European PETACC8 trial 
which enrolled RAS wild-type patients [72]. Edrecolomab is a murine monoclonal 
antibody against EpCam antigen. Addition of edrecolomab to standard 5FU based 
adjuvant therapy did not improve disease-free survival or overall survival in stage 
III colon cancer [73]. Raltitrexed is a quinazoline folate analogue that acts as a direct 
and specific thymidylate synthase inhibitor which is often utilized in patients who 
experience cardiac toxicity with 5FU based therapy. PETACC1 trial examined the 
role of adjuvant raltitrexed in stage III colon cancer compared to 5FU/leucovorin. 
This trial was closed prematurely due to high rate of treatment related toxicity and 
death. However, an independent review found multiple incidences of protocol 
violations in relation to dose adjustment for renal function. Therefore, it may be 
appropriate to consider raltitrexed as an alternative to 5FU in patients with high 
risk stage III colon cancer who experience significant cardiac toxicity. Appropriate 
discussion about the evidence and potential toxicity is key in such instances [74, 75].
Non-steroidal anti-inflammatory (NSAID) drugs like aspirin or celecoxib have 
been examined as adjunctive therapies, however large randomized trial data are 
lacking. Most of the evidence supporting the use of aspirin in secondary prevention 
of colon cancer recurrence are from observational studies, though not all studies 
are consistent. Subset analysis of number of such studies have identified potential 
link to PIK3CA status, prostaglandin-endoperoxidase synthase 2 expression, and 
BRAF mutations. Although these data are interesting, they need to be confirmed 
in prospective trials. A large randomized controlled study examined the benefit 
of celecoxib in more than 2500 patients and there was no disease-free survival or 
overall survival benefit from the addition of celecoxib. Therefore updated 2013 
American Society for Clinical Oncology (ASCO) guidelines did not endorse rou-
tine use of aspirin in this setting [76, 77]. Therefore, routine use of NSAIDs is not 
recommended currently until further studies are available. An association between 
serum vitamin D levels and resected colon cancer has been postulated; however, 
there is no high-quality evidence to support the routine use of vitamin D for this 
indication. Given the adverse of effect of vitamin D deficiency in skeletal system, it 
is not unreasonable to replace vitamin D in those who are deficient.
9. Surveillance
Aim of surveillance after curative resection of primary colorectal cancer is to 
identify asymptomatic recurrences who may be a potential candidate for curative 
resection. Although most randomized trials suggest modest survival benefit, not all 
trials are consistent. The benefit Intensive versus less intensive follow up strategies 
is still debated. Accordingly, surveillance strategies vary among different expert 
groups. Multiple meta-analyses have been conducted in an attempt to rationalize 
the surveillance plan, the latest being Cochrane analysis 2019, which examined 
the data from 13,216 patients from 19 randomized trials and found there was no 
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overall survival benefit from intensive surveillance. Intensive follow up resulted in 
higher rates of salvage surgeries with curative intent; however, this did not result in 
improved survival. Furthermore, these results were confounded by heterogeneity 
of the trials included in the meta-analyses. For example, definition of intensive 
versus less intensive follow up varied among the trials in terms of frequency of 
follow up [78]. In addition some trials included patents with stage I disease who 
have low rates of recurrence. Despite inconsistencies in the data, and the fact that 
curative metastasectomy improves survival in colorectal cancer patients, intensity 
of follow up should be tailored according to patient and cancer characteristics. 
Surveillance modalities include physical examination, carcino-embryonic antigen 
(CEA) and computerized tomography (CT) for surveillance. Follow up guidelines 
varies between the expert groups [79, 80]. A relatively intense follow up is reason-
able for the first 3 years after the curative surgery, with 3–6 monthly physical 
examination and measurement of CEA. A 12 monthly CT scan is appropriate for the 
first 3 years and CT scans should be performed on any clinical suspicion thereafter. 
A colonoscopy is indicated after adjuvant therapy, if a complete colonoscopy was 
not performed at the time of surgery. Otherwise a routine colonoscopy should be 
performed at 12 months and then 5-yearly unless an adenomatous polyp is found 
which should prompt an earlier follow up colonoscopy.
10. Conclusion
Colon cancer is one of the leading cause or morbidity and mortality in the world 
with incidence increasing, especially in younger population. Advances in systemic 
chemotherapeutic options have improved the survival. Adjuvant chemotherapy 
has been shown to reduce the risk of recurrence after resection of primary colon 
cancer; however, it is associated with chemotherapy related morbidity and mortal-
ity. Clinicopathological features and molecular characteristics of the tumor need to 
be carefully assessed and adjuvant therapy should be tailored accordingly in order 
to avoid futile treatment and serious toxicities. Advances in genomic profiling and 
evolution of detection of circulating tumor DNA are promising and may guide the 
choice and intensity of treatment in the future.
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